What does this research mean for the field?

METTL3 drives tumor immune escape by modulating tumor cell metabolic reprogramming and immune cell functional regulation, making it a highly promising anti-tumor therapeutic target. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To comprehensively synthesize current evidence on the structure, biological functions, and molecular regulatory networks of METTL3, specifically emphasizing its roles in tumor immune escape and potential as a therapeutic target.

September 14, 2026Journal of Translational MedicineOpen Access

Methyltransferase-like 3: structure, biological function and role in tumor immune escape and treatment

View Full Paper

Ask AI

Bookmark

Authors

GLGuiyan LiuZunyi Medical University YZYiling ZhuZunyi Medical University JZJiayi ZhangUniversity of Shanghai for Science and Technology

Discussion

Member takes

Implication

Review reveals that METTL3 promotes tumor immune escape and metabolic reprogramming across various cancers, highlighting its promise as a target for anti-tumor immunotherapy.

Key Points

To comprehensively synthesize current evidence on the structure, biological functions, and molecular regulatory networks of METTL3, specifically emphasizing its roles in tumor immune escape and potential as a therapeutic target.
Synthesized molecular and preclinical findings examining METTL3-mediated post-transcriptional gene regulation across malignancies including acute myelogenous leukemia, pancreatic cancer, and colorectal cancer.
Analyzed mechanistic pathways linking METTL3 activity to intrinsic cancer cell metabolic reprogramming and functional phenotypic shifts in tumor-infiltrating immune cells.
Identified METTL3 as a central molecular regulator that facilitates tumor immune escape via dual mechanisms: driving intrinsic metabolic reprogramming in tumor cells and reshaping the functions of infiltrating immune cells.
Highlighted that METTL3 expression profiles correlate with tumor progression and alter therapeutic response to cancer immunotherapies across diverse hematologic and solid malignancies.
Identified high-affinity targeted inhibition of METTL3 and deeper dissection of its immune evasion networks as critical prerequisites for translating METTL3-directed therapies into clinical benefit.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3ee0926e14a848b3528 https://doi.org/10.1186/s12967-026-08960-y

View Full Paper

Ask AI

Bookmark

September 14, 2026Journal of Translational MedicineOpen Access

Methyltransferase-like 3: structure, biological function and role in tumor immune escape and treatment

View Full Paper

Ask AI

Bookmark

Authors

GLGuiyan LiuZunyi Medical University YZYiling ZhuZunyi Medical University JZJiayi ZhangUniversity of Shanghai for Science and Technology

Discussion

Member takes

Implication

Review reveals that METTL3 promotes tumor immune escape and metabolic reprogramming across various cancers, highlighting its promise as a target for anti-tumor immunotherapy.

Key Points

To comprehensively synthesize current evidence on the structure, biological functions, and molecular regulatory networks of METTL3, specifically emphasizing its roles in tumor immune escape and potential as a therapeutic target.
Synthesized molecular and preclinical findings examining METTL3-mediated post-transcriptional gene regulation across malignancies including acute myelogenous leukemia, pancreatic cancer, and colorectal cancer.
Analyzed mechanistic pathways linking METTL3 activity to intrinsic cancer cell metabolic reprogramming and functional phenotypic shifts in tumor-infiltrating immune cells.
Identified METTL3 as a central molecular regulator that facilitates tumor immune escape via dual mechanisms: driving intrinsic metabolic reprogramming in tumor cells and reshaping the functions of infiltrating immune cells.
Highlighted that METTL3 expression profiles correlate with tumor progression and alter therapeutic response to cancer immunotherapies across diverse hematologic and solid malignancies.
Identified high-affinity targeted inhibition of METTL3 and deeper dissection of its immune evasion networks as critical prerequisites for translating METTL3-directed therapies into clinical benefit.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3ee0926e14a848b3528 https://doi.org/10.1186/s12967-026-08960-y

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark